Ralph J. Hauke

5.8k citations

101 papers · 2.7k indexed · 1 hit paper · h-index 25

Oncology top 2%
Molecular Biology top 10%
Pulmonary and Respiratory Medicine top 2%
Surgery top 5%
Cancer Research top 5%

Co-authors: Murielle Mimeault Surinder K. Batra Parmender P. Mehta R. Bryan Rumble Matthew I. Milowsky Stefano Tarantolo Jamés O. Armitage Christopher M. Booth
Topics: Cancer Immunotherapy and Biomarkers (29 papers)Renal cell carcinoma treatment (28 papers)Bladder and Urothelial Cancer Treatments (19 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical OncologySHILAP Revista de lepidopterologíaEndocrine Reviews
Partner nations: United States United Kingdom Spain

In The Last Decade

Ralph J. Hauke

97 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

2022 175 citations Peter J. Van Veldhuizen, Hamid Emamekhoo et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ralph J. Hauke

Since Specialization

Citations

This map shows the geographic impact of Ralph J. Hauke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralph J. Hauke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralph J. Hauke more than expected).

Fields of papers citing papers by Ralph J. Hauke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralph J. Hauke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralph J. Hauke. The network helps show where Ralph J. Hauke may publish in the future.

Co-authorship network of co-authors of Ralph J. Hauke

This figure shows the co-authorship network connecting the top 25 collaborators of Ralph J. Hauke. A scholar is included among the top collaborators of Ralph J. Hauke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralph J. Hauke. Ralph J. Hauke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. 2025 ·Journal of Clinical Oncology ·Toni K. Choueiri,Jae‐Lyun Lee,Jaime R. Merchan,Amita Patnaik,(unknown),Alexandra Drakaki,Moshe Chaim Ornstein,Bradley A. McGregor,Ralph J. Hauke,(unknown),Brian I. Rini,Pedro C. Barata,Paul Foster,Sutapa Mukhopadhyay,(unknown),(unknown),Manish Monga,Dimitry S.A. Nuyten,Sun Young Rha	0
2	COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts 2025 ·Journal of Clinical Oncology ·Sumanta K. Pal,Yohann Loriot,Andrea Necchi,(unknown),Daniel Castellano,Lance C. Pagliaro,Cristina Suárez,Bradley A. McGregor,Ulka N. Vaishampayan,Ralph J. Hauke,Thomas Powles,Carla M.L. van Herpen,Kevin D. Courtney,Robert Dreicer,Ramu Sudhagoni,(unknown),(unknown),Neeraj Agarwal	0
3	742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors 2023 ·SHILAP Revista de lepidopterología ·Jong Chul Park,David Berz,Manish Sharma,Erminia Massarelli,Ralph J. Hauke,Frank Tsai,David S. Hong,(unknown),Justin Call,Jennifer W. Carlisle,Rachel E. Sanborn,Naomi B. Haas,John Hamm,D. Ross Camidge,Alexander I. Spira,(unknown),(unknown),(unknown),Anthony W. Tolcher	2
4	SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma 2023 ·Clinical Cancer Research ·Lisa A. Kottschade,Gregory R. Pond,Anthony J. Olszanski,Yousef Zakharia,Evidio Domingo‐Musibay,Ralph J. Hauke,Brendan D. Curti,(unknown),Mohammed Milhem,Matthew S. Block,Tina J. Hieken,Robert R. McWilliams	7
5	A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy 2023 ·Clinical Cancer Research ·Sarah A. Weiss,Mario Sznol,Montaser Shaheen,Miguel‐Ángel Berciano‐Guerrero,Eva Muñoz‐Couselo,Delvys Rodríguez‐Abreu,Valentina Boni,Lynn M. Schuchter,María González‐Cao,Ana Arance,Wei Wei,Apar Kishor Ganti,Ralph J. Hauke,Alfonso Berrocal,Nicholas Iannotti,(unknown),Harriet M. Kluger	28
6	Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023 2023 ·Journal for ImmunoTherapy of Cancer ·Monika Joshi,Leonard Tuanquin,Junjia Zhu,Vonn Walter,Todd D. Schell,Matthew Kaag,Deepak Kilari,Jiangang Liao,Sheldon L. Holder,Hamid Emamekhoo,Alexander Sankin,(unknown),Hong Zheng,(unknown),Ralph J. Hauke,(unknown),Mark N. Stein,Joseph J. Drabick,David J. DeGraff,Yousef Zakharia	18
7	A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC 2023 ·The Oncologist ·Eric Jonasch,Ralph J. Hauke,Gerald S. Falchook,Theodore F. Logan,Michael S. Gordon,Evan Hall,(unknown),Mehmet Asım Bilen,Abdul Rafeh Naqash,(unknown),Christopher W. Ryan,Satwant Lally,Jim Xiao,Zachary Zimmerman,Ramaprasad Srinivasan,Toni K. Choueiri	1
8	A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer 2022 ·Clinical Genitourinary Cancer ·Neal D. Shore,Begoña Mellado,(unknown),Ralph J. Hauke,(unknown),Nabil Adra,Marie Cullberg,(unknown),Thomas Morris	15
9	An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma 2021 ·OncoImmunology ·(unknown),Denái R. Milton,William H. Sharfman,Bret Taback,Lee D. Cranmer,Gregory A. Daniels,Lawrence E. Flaherty,Sigrun Hallmeyer,Mohammed Milhem,Lynn G. Feun,Ralph J. Hauke,Gary C. Doolittle,(unknown),Sapna P. Patel	5
10	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2 2021 ·Journal of Investigative Medicine ·Joseph I. Clark,Brendan D. Curti,Elizabeth J. Davis,Howard L. Kaufman,Asim Amin,Ajjai Alva,Theodore F. Logan,Ralph J. Hauke,(unknown),Ulka N. Vaishampayan,Douglas B. Johnson,Richard L. White,Peter H. Wiernik,Janice P. Dutcher	15
11	Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study 2020 ·Clinical Genitourinary Cancer ·Joshua J. McFarlane,Mark D. Kochenderfer,Mark R. Olsen,Todd M. Bauer,Ana M. Molina,Ralph J. Hauke,James A. Reeves,Sunil Babu,Peter J. Van Veldhuizen,Bradley G. Somer,Vijay Gunuganti,Ian D. Schnadig,Saby George,Ray D. Page,Edward Arrowsmith,Rohit Jain,Joshua Zhang,M. Brent McHenry,Jennifer L. Johansen,Nicholas J. Vogelzang	29
12	Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry 2019 ·Journal for ImmunoTherapy of Cancer ·Mayer Fishman,Janice P. Dutcher,Joseph I. Clark,Ajjai Alva,(unknown),Brendan D. Curti,Neeraj Agarwal,Ralph J. Hauke,Kathleen M. Mahoney,(unknown),Jonathan Treisman,Scott S. Tykodi,Gregory A. Daniels,Michael A. Morse,Michael K. Wong,Howard L. Kaufman,(unknown),David F. McDermott	41
13	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study 2018 ·Lung Cancer ·Shirish M. Gadgeel,James Stevenson,Corey J. Langer,Leena Gandhi,Hossein Borghaei,Amita Patnaik,Liza C. Villaruz,Matthew A. Gubens,Ralph J. Hauke,James Chih‐Hsin Yang,Lecia V. Sequist,Robert Bachman,Sanatan Saraf,Harry Raftopoulos,Vassiliki A. Papadimitrakopoulou	68
14	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone 2017 ·Clinical Cancer Research ·Dana E. Rathkopf,Emmanuel S. Antonarakis,Neal D. Shore,Ronald Tutrone,Joshi J. Alumkal,Charles J. Ryan,Mansoor N. Saleh,Ralph J. Hauke,Rajesh Bandekar,Edna Chow Maneval,Carla J. de Boer,Margaret K. Yu,Howard I. Scher	64
15	Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now 2014 ·Journal of Clinical Oncology ·Ann H. Partridge,Davinia Seah,(unknown),Natasha B. Leighl,Ralph J. Hauke,Dana S. Wollins,Jamie H. Von Roenn	69
16	Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma 2013 ·European Journal of Cancer ·Mayer Fishman,S. Srinivas,Ralph J. Hauke,R. J. Amato,(unknown),Monette Cotreau,Andrew Strahs,William J. Slichenmyer,Pankaj Bhargava,Fairooz F. Kabbinavar	25
17	Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab 2011 ·SHILAP Revista de lepidopterología ·Subhankar Chakraborty,Stefano Tarantolo,(unknown),(unknown),Ralph J. Hauke,Surinder K. Batra	9
18	Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades 2007 ·Growth Factors ·Murielle Mimeault,Parmender P. Mehta,Ralph J. Hauke,Jean-Pierre Hénichart,Patrick Depreux,Ming‐Fong Lin,Surinder K. Batra	19
19	Novel C5a Agonist-Based Dendritic Cell Vaccine in a Murine Model of Melanoma 2007 ·Cell Cycle ·Anthony A. Floreani,Sandra J. Gunselman,(unknown),Ralph J. Hauke,Stefano Tarantolo,John D. Jackson	13
20	ERK inhibitor PD98059 enhances docetaxel‐induced apoptosis of androgen‐independent human prostate cancer cells 2003 ·International Journal of Cancer ·Stanislav Zelivianski,(unknown),(unknown),(unknown),(unknown),(unknown),Ming‐Shyue Lee,R. Taylor,Thomas L. Davis,Ralph J. Hauke,Ming‐Fong Lin	118

About Ralph J. Hauke

Ralph J. Hauke is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 101 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (29 papers), Renal cell carcinoma treatment (28 papers) and Bladder and Urothelial Cancer Treatments (19 papers). The work is most often cited by research in Oncology (1.2k citations), Pulmonary and Respiratory Medicine (927 citations) and Cancer Research (418 citations). Ralph J. Hauke has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Murielle Mimeault, Surinder K. Batra, Parmender P. Mehta, Surinder K. Batra, R. Bryan Rumble, Matthew I. Milowsky, Stefano Tarantolo, Jamés O. Armitage, Christopher M. Booth and Cheryl T. Lee. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Endocrine Reviews.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact